All Categories
| Product Name | Description | Action |
|---|---|---|
| Amivantamab ,Rybrevant ,EGFR, cMet (MET) ,JNJ-61186372 ,EGFR/c-MET bispecific antibody ,Fully human IgG1 bispecific ,Oncology immunotherapy / NSCLC biologic ,CAS No.2171511-58-1 | Trade Name : Rybrevant Target : EGFR, cMet (MET) Molecular Type : Bispecific Antibody Sales in 2025 (Millions of USD) : 179(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in ... |
|
| Polatuzumab vedotin ,Polivy ,CD79B ,RG7596 ,ADC ,CD79b-targeted therapy ,Microtubule inhibitor ,Oncology ADC / DLBCL ADC / Lymphoma ADC ,Intravenous infusion ,CAS No.1313206-42-6 | Trade Name : Polivy Target : CD79B Molecular Type : ADC Sales in 2025 (Millions of USD) : 850(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Obinutuzumab ,Gazyva ,CD20 ,GA101 ,CAS No.949142-50-1 ,Anti-CD20 monoclonal antibody (Type II) ,Humanized glycoengineered IgG1 antibody ,Oncology biologic / CLL biologic / Follicular lymphoma biologic | Trade Name : Gazyva Target : CD20 Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 784(First three quarters) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Ivonescimab ,YIDAFANG®(Trade names approved for use in China) ,AK112 ,PD-1/VEGF bispecific antibody ,Oncology immunotherapy / Anti-angiogenic therapy ,PD-1/VEGF Bispecific antibod ,CAS No.2428381-53-5 | Trade Name : YIDAFANG® (Trade names approved for use in China) Target : N/A Molecular Type : PD-1/VEGF Bispecific antibody Sales in 2025 (Millions of USD) : 28(In 2024) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this ... |
|
| Datopotamab deruxtecan-dlnk ,Datroway ,TROP-2 ,DS-1062 ,ADC ,TROP2-targeted therapy ,Topoisomerase I inhibitor ,Oncology ADC / NSCLC ADC / Breast cancer ADC ,CAS No.2238831-60-0 | Trade Name : Datroway Target : TROP-2 Molecular Type : ADC Sales in 2025 (Millions of USD) : 10(First Quarter) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Tenecteplase ,Metalyse ,Fibrin ,TNK-tPA ,Thrombolytic / Fibrinolytic enzyme ,Third-generation tPA ,Recombinant Protein ,CAS No.191588-94-0 | Trade Name : Metalyse Target : Fibrin Molecular Type : Recombinant Protein Sales in 2025 (Millions of USD) : 1780(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Tarlatamab ,Imdelltra ,DLL3&CD3 ,AMG 757 ,Oncology immunotherapy / SCLC biologic ,Intravenous infusion ,T-cell mediated cytotoxicity ,Bispecific T-cell Engager ,CAS No.2307488-83-9 | Trade Name : Imdelltra Target : DLL3&CD3 Molecular Type : Bispecific T-cell Engager Sales in 2025 (Millions of USD) : 215(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in ... |
|
| Serplulimab ,HANSIZHUANG ,PD-1 ,Hetronifly ,HLX10 ,Anti-PD-1 immune checkpoint inhibitor ,Humanized IgG4 monoclonal antibody ,Monoclonal Antibody ,CAS No.2231029-82-4 | Trade Name : HANSIZHUANG Target : PD-1 Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 82(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with ... |
